Cryopyrin-Associated Periodic Syndromes – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cryopyrin-Associated Periodic Syndromes – Drugs In Development, 2024 report and make more profitable business decisions.
cryopyrin-associated periodic syndromes are a group of autoimmune diseases caused by a defect in the cryopyrin protein. Genetic mutations on the NLRP3 gene result in overproduction of interleukin 1 beta due to excessive inflammasome activation. This is generally seen in children and is a rare form. It includes Neonatal Onset Multisystem Inflammatory Disease (NOMID), Muckle-Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS). Symptoms are variable based on the individual conditions. Cold, fatigue, painful or burning rash, fever, joint pains, headache, and nausea are common symptoms. Diagnosis is difficult but based on physical examination and complete blood count to find out the levels of inflammatory mediators, skin biopsy and other lab examinations done. Anti inflammatory drugs to treat inflammation and supportive care are management steps.
The Cryopyrin-Associated Periodic Syndromes drugs in development market research report provide comprehensive information on the therapeutics under development for Cryopyrin-Associated Periodic Syndromes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryopyrin-Associated Periodic Syndromes and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cryopyrin-Associated Periodic Syndromes | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cryopyrin-Associated Periodic Syndromes therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cryopyrin-Associated Periodic Syndromes pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cryopyrin-Associated Periodic Syndromes treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
9 Meters Biopharma IncF. Hoffmann-La Roche Ltd
Mabpharm Ltd
Novartis AG
Secarna Pharmaceuticals GmbH & Co KG
Swedish Orphan Biovitrum AB
Ventyx Biosciences Inc
Xylonix Pte Ltd
Yale University
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cryopyrin-Associated Periodic Syndromes reports